Clinical Trial Update: A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

This Phase 3 trial compared the fixed-dose triple inhaled regimen Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) to Budesonide/Formoterol in adults wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort (budesonide/formoterol)
• Trelegy Ellipta (FF/UMEC/VI) (Fluticasone furoate/umeclidinium/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2018-07-13